Efficacy of continuing sglt2 inhibitors on outcomes in patients with acute decompensated heart failure

12Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

Abstract

Sodium-glucose cotransporter 2 inhibitor (SGLT2i) reduces mortality and morbidity in patients with chronic heart failure (HF). However, the clinical implication of SGLT2i therapy in patients with acute decom-pensated HF remains uncertain. We prospectively studied 86 type 2 diabetic mellitus (T2DM) patients (71.8 ± 12.1 years, 55 men) who were hospitalized for acute decompensated HF and received SGLT2i during the index hospitalization. Among the patients, 56 continued SGLT2i at discharge and 30 did not. The continued group ex-perienced fewer HF re-hospitalizations than the discontinued group (24% versus 39%, P = 0.008) with a hazard ratio of 0.29 (95% confidence interval 0.10-0.85) adjusted for other significant potential confounders. In conclusion, long-term SGLT2i therapy might prevent unplanned HF re-hospitalization in patients with T2DM and acute decompensated HF.

Cite

CITATION STYLE

APA

Nakagaito, M., Imamura, T., Joho, S., Ushijima, R., Nakamura, M., & Kinugawa, K. (2021). Efficacy of continuing sglt2 inhibitors on outcomes in patients with acute decompensated heart failure. International Heart Journal, 62(4), 885–890. https://doi.org/10.1536/ihj.21-022

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free